Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Sarcoma 2Head & Neck 2Genitourinary 2Breast 2Other solid neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Lymphoma 8Lymphoma, Extranodal NK-T-Cell 6Neoplasm Metastasis 3Sarcoma 2Lymphoma, Large B-Cell, Diffuse 2Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Immunoblastic Lymphadenopathy 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × spartalizumab × Lymphoid × Clear all
NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Novartis

Phase 2 Completed
76 enrolled 14 charts
GastrointestinalLymphoidSarcomaThoracic

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡